U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Google Secures Pentagon AI Deal for Classified Projects 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
MORRISTOWN, N.J., May 08, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2017, after the market close on Monday, May 15, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Monday, May 15 | ||
| Time: | 4:30 PM ET | ||
| Toll free (U.S.): | 888-504-7953 | ||
| International: | 719-457-2643 | ||
| Conference ID: | 4336660 | ||
| Webcast: | http://public.viavid.com/index.php?id=124373 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]
